nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—ABCG2—Sulfasalazine—ankylosing spondylitis	0.0754	0.111	CbGbCtD
Imatinib—PTGS1—Sulfasalazine—ankylosing spondylitis	0.0696	0.102	CbGbCtD
Imatinib—CYP3A5—Sulfasalazine—ankylosing spondylitis	0.0418	0.0615	CbGbCtD
Imatinib—ALB—Prednisone—ankylosing spondylitis	0.0415	0.0612	CbGbCtD
Imatinib—ABCG2—Dexamethasone—ankylosing spondylitis	0.0376	0.0554	CbGbCtD
Imatinib—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0359	0.0528	CbGbCtD
Imatinib—ABCG2—Methotrexate—ankylosing spondylitis	0.0302	0.0445	CbGbCtD
Imatinib—CYP3A7—Dexamethasone—ankylosing spondylitis	0.0278	0.0409	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Dexamethasone—ankylosing spondylitis	0.0278	0.0409	CbGbCtD
Imatinib—CYP2C19—Prednisone—ankylosing spondylitis	0.0269	0.0397	CbGbCtD
Imatinib—ABCB1—Betamethasone—ankylosing spondylitis	0.0233	0.0343	CbGbCtD
Imatinib—ABCB1—Prednisolone—ankylosing spondylitis	0.023	0.0339	CbGbCtD
Imatinib—ABCB1—Prednisone—ankylosing spondylitis	0.0217	0.032	CbGbCtD
Imatinib—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0215	0.0317	CbGbCtD
Imatinib—CYP3A5—Dexamethasone—ankylosing spondylitis	0.0208	0.0307	CbGbCtD
Imatinib—ALB—Methotrexate—ankylosing spondylitis	0.0208	0.0307	CbGbCtD
Imatinib—CYP2C19—Dexamethasone—ankylosing spondylitis	0.0168	0.0248	CbGbCtD
Imatinib—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0163	0.024	CbGbCtD
Imatinib—CYP2C9—Dexamethasone—ankylosing spondylitis	0.014	0.0206	CbGbCtD
Imatinib—CYP3A4—Betamethasone—ankylosing spondylitis	0.014	0.0206	CbGbCtD
Imatinib—CYP3A4—Prednisolone—ankylosing spondylitis	0.0138	0.0203	CbGbCtD
Imatinib—ABCB1—Dexamethasone—ankylosing spondylitis	0.0136	0.02	CbGbCtD
Imatinib—CYP3A4—Prednisone—ankylosing spondylitis	0.013	0.0192	CbGbCtD
Imatinib—CYP2D6—Dexamethasone—ankylosing spondylitis	0.0128	0.0188	CbGbCtD
Imatinib—ABCB1—Methotrexate—ankylosing spondylitis	0.0109	0.0161	CbGbCtD
Imatinib—CYP3A4—Dexamethasone—ankylosing spondylitis	0.00813	0.012	CbGbCtD
Imatinib—ABCA3—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000762	0.0416	CbGpPWpGaD
Imatinib—DDR1—Extracellular matrix organization—MMP3—ankylosing spondylitis	0.000427	0.0233	CbGpPWpGaD
Imatinib—LCK—Inflammatory Response Pathway—TNFRSF1B—ankylosing spondylitis	0.000362	0.0197	CbGpPWpGaD
Imatinib—NTRK1—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.000325	0.0178	CbGpPWpGaD
Imatinib—PTGS1—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	0.000305	0.0166	CbGpPWpGaD
Imatinib—SLC47A1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000282	0.0154	CbGpPWpGaD
Imatinib—LCK—Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters—HLA-A—ankylosing spondylitis	0.000257	0.014	CbGpPWpGaD
Imatinib—PTGS1—Overview of nanoparticle effects—CRP—ankylosing spondylitis	0.000247	0.0135	CbGpPWpGaD
Imatinib—NTRK1—p75(NTR)-mediated signaling—MMP3—ankylosing spondylitis	0.000239	0.013	CbGpPWpGaD
Imatinib—LCK—Signaling by Interleukins—IL1R2—ankylosing spondylitis	0.000232	0.0127	CbGpPWpGaD
Imatinib—PDGFRA—Allograft Rejection—HLA-C—ankylosing spondylitis	0.000225	0.0123	CbGpPWpGaD
Imatinib—PDGFRB—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—MMP3—ankylosing spondylitis	0.000222	0.0121	CbGpPWpGaD
Imatinib—LCK—Inflammatory Response Pathway—CD40LG—ankylosing spondylitis	0.000219	0.012	CbGpPWpGaD
Imatinib—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.00021	0.000694	CcSEcCtD
Imatinib—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.00021	0.000693	CcSEcCtD
Imatinib—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.00021	0.000692	CcSEcCtD
Imatinib—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.00021	0.000692	CcSEcCtD
Imatinib—Epistaxis—Methotrexate—ankylosing spondylitis	0.000209	0.000692	CcSEcCtD
Imatinib—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000209	0.000692	CcSEcCtD
Imatinib—Tachycardia—Triamcinolone—ankylosing spondylitis	0.000209	0.000691	CcSEcCtD
Imatinib—Mental disorder—Prednisone—ankylosing spondylitis	0.000209	0.00069	CcSEcCtD
Imatinib—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.000209	0.00069	CcSEcCtD
Imatinib—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000208	0.000687	CcSEcCtD
Imatinib—Malnutrition—Prednisone—ankylosing spondylitis	0.000208	0.000686	CcSEcCtD
Imatinib—Erythema—Prednisone—ankylosing spondylitis	0.000208	0.000686	CcSEcCtD
Imatinib—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000207	0.000685	CcSEcCtD
Imatinib—Agranulocytosis—Methotrexate—ankylosing spondylitis	0.000207	0.000685	CcSEcCtD
Imatinib—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000207	0.000683	CcSEcCtD
Imatinib—Convulsion—Dexamethasone—ankylosing spondylitis	0.000207	0.000682	CcSEcCtD
Imatinib—Convulsion—Betamethasone—ankylosing spondylitis	0.000207	0.000682	CcSEcCtD
Imatinib—Hypertension—Betamethasone—ankylosing spondylitis	0.000206	0.00068	CcSEcCtD
Imatinib—Hypertension—Dexamethasone—ankylosing spondylitis	0.000206	0.00068	CcSEcCtD
Imatinib—PDGFRA—Allograft Rejection—IL17A—ankylosing spondylitis	0.000205	0.0112	CbGpPWpGaD
Imatinib—LCK—The role of Nef in HIV-1 replication and disease pathogenesis—HLA-A—ankylosing spondylitis	0.000204	0.0111	CbGpPWpGaD
Imatinib—PDGFRB—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.000203	0.0111	CbGpPWpGaD
Imatinib—Myalgia—Betamethasone—ankylosing spondylitis	0.000203	0.000671	CcSEcCtD
Imatinib—Myalgia—Dexamethasone—ankylosing spondylitis	0.000203	0.000671	CcSEcCtD
Imatinib—Anxiety—Betamethasone—ankylosing spondylitis	0.000202	0.000668	CcSEcCtD
Imatinib—Anxiety—Dexamethasone—ankylosing spondylitis	0.000202	0.000668	CcSEcCtD
Imatinib—Discomfort—Dexamethasone—ankylosing spondylitis	0.000201	0.000662	CcSEcCtD
Imatinib—Discomfort—Betamethasone—ankylosing spondylitis	0.000201	0.000662	CcSEcCtD
Imatinib—Haemoglobin—Methotrexate—ankylosing spondylitis	0.0002	0.000662	CcSEcCtD
Imatinib—Hypotension—Methylprednisolone—ankylosing spondylitis	0.0002	0.00066	CcSEcCtD
Imatinib—Pain—Prednisolone—ankylosing spondylitis	0.000199	0.000659	CcSEcCtD
Imatinib—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000199	0.000658	CcSEcCtD
Imatinib—Hepatitis—Methotrexate—ankylosing spondylitis	0.000199	0.000658	CcSEcCtD
Imatinib—Pharyngitis—Methotrexate—ankylosing spondylitis	0.000198	0.000654	CcSEcCtD
Imatinib—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000197	0.00065	CcSEcCtD
Imatinib—Vision blurred—Prednisone—ankylosing spondylitis	0.000196	0.000646	CcSEcCtD
Imatinib—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000195	0.000645	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000195	0.000645	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000195	0.000644	CcSEcCtD
Imatinib—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.000195	0.000643	CcSEcCtD
Imatinib—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.000195	0.000643	CcSEcCtD
Imatinib—Oedema—Betamethasone—ankylosing spondylitis	0.000195	0.000643	CcSEcCtD
Imatinib—Oedema—Dexamethasone—ankylosing spondylitis	0.000195	0.000643	CcSEcCtD
Imatinib—ABL1—Posttranslational regulation of adherens junction stability and dissassembly—MMP3—ankylosing spondylitis	0.000194	0.0106	CbGpPWpGaD
Imatinib—Insomnia—Triamcinolone—ankylosing spondylitis	0.000194	0.000641	CcSEcCtD
Imatinib—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000193	0.000639	CcSEcCtD
Imatinib—Infection—Dexamethasone—ankylosing spondylitis	0.000193	0.000639	CcSEcCtD
Imatinib—Infection—Betamethasone—ankylosing spondylitis	0.000193	0.000639	CcSEcCtD
Imatinib—Ill-defined disorder—Prednisone—ankylosing spondylitis	0.000193	0.000636	CcSEcCtD
Imatinib—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.000193	0.000636	CcSEcCtD
Imatinib—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.000192	0.000635	CcSEcCtD
Imatinib—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.000192	0.000635	CcSEcCtD
Imatinib—Anaemia—Prednisone—ankylosing spondylitis	0.000192	0.000634	CcSEcCtD
Imatinib—Shock—Dexamethasone—ankylosing spondylitis	0.000191	0.000632	CcSEcCtD
Imatinib—Shock—Betamethasone—ankylosing spondylitis	0.000191	0.000632	CcSEcCtD
Imatinib—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000191	0.000632	CcSEcCtD
Imatinib—PDGFRA—Allograft Rejection—IL12B—ankylosing spondylitis	0.000191	0.0104	CbGpPWpGaD
Imatinib—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000191	0.00063	CcSEcCtD
Imatinib—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000191	0.00063	CcSEcCtD
Imatinib—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.00019	0.000629	CcSEcCtD
Imatinib—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.00019	0.000629	CcSEcCtD
Imatinib—Tachycardia—Dexamethasone—ankylosing spondylitis	0.00019	0.000627	CcSEcCtD
Imatinib—Tachycardia—Betamethasone—ankylosing spondylitis	0.00019	0.000627	CcSEcCtD
Imatinib—Angioedema—Prednisone—ankylosing spondylitis	0.00019	0.000627	CcSEcCtD
Imatinib—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.000189	0.000624	CcSEcCtD
Imatinib—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.000188	0.000623	CcSEcCtD
Imatinib—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.000188	0.000622	CcSEcCtD
Imatinib—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000188	0.000621	CcSEcCtD
Imatinib—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000188	0.000621	CcSEcCtD
Imatinib—Malaise—Prednisone—ankylosing spondylitis	0.000187	0.000619	CcSEcCtD
Imatinib—Vertigo—Prednisone—ankylosing spondylitis	0.000187	0.000616	CcSEcCtD
Imatinib—Eye disorder—Methotrexate—ankylosing spondylitis	0.000186	0.000615	CcSEcCtD
Imatinib—Syncope—Prednisone—ankylosing spondylitis	0.000186	0.000615	CcSEcCtD
Imatinib—Tinnitus—Methotrexate—ankylosing spondylitis	0.000186	0.000614	CcSEcCtD
Imatinib—Anorexia—Dexamethasone—ankylosing spondylitis	0.000185	0.000613	CcSEcCtD
Imatinib—Anorexia—Betamethasone—ankylosing spondylitis	0.000185	0.000613	CcSEcCtD
Imatinib—Urticaria—Prednisolone—ankylosing spondylitis	0.000185	0.000612	CcSEcCtD
Imatinib—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.000185	0.000611	CcSEcCtD
Imatinib—Fatigue—Triamcinolone—ankylosing spondylitis	0.000185	0.000611	CcSEcCtD
Imatinib—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000184	0.000609	CcSEcCtD
Imatinib—Pain—Triamcinolone—ankylosing spondylitis	0.000183	0.000606	CcSEcCtD
Imatinib—Loss of consciousness—Prednisone—ankylosing spondylitis	0.000182	0.000603	CcSEcCtD
Imatinib—Hypotension—Betamethasone—ankylosing spondylitis	0.000182	0.000601	CcSEcCtD
Imatinib—Hypotension—Dexamethasone—ankylosing spondylitis	0.000182	0.000601	CcSEcCtD
Imatinib—Angiopathy—Methotrexate—ankylosing spondylitis	0.000181	0.000597	CcSEcCtD
Imatinib—Immune system disorder—Methotrexate—ankylosing spondylitis	0.00018	0.000595	CcSEcCtD
Imatinib—Convulsion—Prednisone—ankylosing spondylitis	0.00018	0.000594	CcSEcCtD
Imatinib—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.00018	0.000593	CcSEcCtD
Imatinib—Hypertension—Prednisone—ankylosing spondylitis	0.000179	0.000592	CcSEcCtD
Imatinib—Chills—Methotrexate—ankylosing spondylitis	0.000179	0.000591	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.000177	0.000586	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.000177	0.000586	CcSEcCtD
Imatinib—Myalgia—Prednisone—ankylosing spondylitis	0.000177	0.000584	CcSEcCtD
Imatinib—Arthralgia—Prednisone—ankylosing spondylitis	0.000177	0.000584	CcSEcCtD
Imatinib—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.000177	0.000584	CcSEcCtD
Imatinib—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.000176	0.000582	CcSEcCtD
Imatinib—Anxiety—Prednisone—ankylosing spondylitis	0.000176	0.000582	CcSEcCtD
Imatinib—Alopecia—Methotrexate—ankylosing spondylitis	0.000176	0.000582	CcSEcCtD
Imatinib—Insomnia—Betamethasone—ankylosing spondylitis	0.000176	0.000581	CcSEcCtD
Imatinib—Insomnia—Dexamethasone—ankylosing spondylitis	0.000176	0.000581	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000176	0.00058	CcSEcCtD
Imatinib—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000175	0.000578	CcSEcCtD
Imatinib—Paraesthesia—Betamethasone—ankylosing spondylitis	0.000175	0.000577	CcSEcCtD
Imatinib—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.000175	0.000577	CcSEcCtD
Imatinib—Discomfort—Prednisone—ankylosing spondylitis	0.000175	0.000577	CcSEcCtD
Imatinib—Mental disorder—Methotrexate—ankylosing spondylitis	0.000175	0.000577	CcSEcCtD
Imatinib—Malnutrition—Methotrexate—ankylosing spondylitis	0.000173	0.000573	CcSEcCtD
Imatinib—Erythema—Methotrexate—ankylosing spondylitis	0.000173	0.000573	CcSEcCtD
Imatinib—LCK—IL12-mediated signaling events—IL12B—ankylosing spondylitis	0.000172	0.00939	CbGpPWpGaD
Imatinib—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000172	0.000568	CcSEcCtD
Imatinib—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.000171	0.000566	CcSEcCtD
Imatinib—Dyspepsia—Betamethasone—ankylosing spondylitis	0.000171	0.000566	CcSEcCtD
Imatinib—Urticaria—Triamcinolone—ankylosing spondylitis	0.00017	0.000563	CcSEcCtD
Imatinib—Urticaria—Methylprednisolone—ankylosing spondylitis	0.00017	0.000562	CcSEcCtD
Imatinib—Dysgeusia—Methotrexate—ankylosing spondylitis	0.00017	0.000561	CcSEcCtD
Imatinib—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000169	0.00056	CcSEcCtD
Imatinib—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.000169	0.00056	CcSEcCtD
Imatinib—Oedema—Prednisone—ankylosing spondylitis	0.000169	0.00056	CcSEcCtD
Imatinib—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000169	0.000559	CcSEcCtD
Imatinib—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000169	0.000559	CcSEcCtD
Imatinib—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000169	0.000559	CcSEcCtD
Imatinib—Infection—Prednisone—ankylosing spondylitis	0.000168	0.000556	CcSEcCtD
Imatinib—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000168	0.000555	CcSEcCtD
Imatinib—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000168	0.000555	CcSEcCtD
Imatinib—Back pain—Methotrexate—ankylosing spondylitis	0.000168	0.000554	CcSEcCtD
Imatinib—Fatigue—Dexamethasone—ankylosing spondylitis	0.000168	0.000554	CcSEcCtD
Imatinib—Fatigue—Betamethasone—ankylosing spondylitis	0.000168	0.000554	CcSEcCtD
Imatinib—Shock—Prednisone—ankylosing spondylitis	0.000167	0.000551	CcSEcCtD
Imatinib—Pain—Dexamethasone—ankylosing spondylitis	0.000166	0.00055	CcSEcCtD
Imatinib—Pain—Betamethasone—ankylosing spondylitis	0.000166	0.00055	CcSEcCtD
Imatinib—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000166	0.000549	CcSEcCtD
Imatinib—Tachycardia—Prednisone—ankylosing spondylitis	0.000165	0.000546	CcSEcCtD
Imatinib—Skin disorder—Prednisone—ankylosing spondylitis	0.000165	0.000544	CcSEcCtD
Imatinib—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000164	0.000541	CcSEcCtD
Imatinib—Vision blurred—Methotrexate—ankylosing spondylitis	0.000164	0.00054	CcSEcCtD
Imatinib—Anorexia—Prednisone—ankylosing spondylitis	0.000161	0.000534	CcSEcCtD
Imatinib—Ill-defined disorder—Methotrexate—ankylosing spondylitis	0.000161	0.000532	CcSEcCtD
Imatinib—Anaemia—Methotrexate—ankylosing spondylitis	0.00016	0.00053	CcSEcCtD
Imatinib—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.00016	0.00053	CcSEcCtD
Imatinib—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.00016	0.00053	CcSEcCtD
Imatinib—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000159	0.000526	CcSEcCtD
Imatinib—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000159	0.000526	CcSEcCtD
Imatinib—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000158	0.000522	CcSEcCtD
Imatinib—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.000158	0.000521	CcSEcCtD
Imatinib—Malaise—Methotrexate—ankylosing spondylitis	0.000156	0.000517	CcSEcCtD
Imatinib—Vertigo—Methotrexate—ankylosing spondylitis	0.000156	0.000515	CcSEcCtD
Imatinib—Leukopenia—Methotrexate—ankylosing spondylitis	0.000155	0.000513	CcSEcCtD
Imatinib—Urticaria—Betamethasone—ankylosing spondylitis	0.000155	0.000511	CcSEcCtD
Imatinib—Urticaria—Dexamethasone—ankylosing spondylitis	0.000155	0.000511	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.000154	0.00051	CcSEcCtD
Imatinib—Dizziness—Prednisolone—ankylosing spondylitis	0.000154	0.000509	CcSEcCtD
Imatinib—Asthenia—Triamcinolone—ankylosing spondylitis	0.000154	0.000508	CcSEcCtD
Imatinib—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000154	0.000508	CcSEcCtD
Imatinib—Abdominal pain—Betamethasone—ankylosing spondylitis	0.000154	0.000508	CcSEcCtD
Imatinib—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000154	0.000508	CcSEcCtD
Imatinib—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.000154	0.000508	CcSEcCtD
Imatinib—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000153	0.000507	CcSEcCtD
Imatinib—Insomnia—Prednisone—ankylosing spondylitis	0.000153	0.000506	CcSEcCtD
Imatinib—Paraesthesia—Prednisone—ankylosing spondylitis	0.000152	0.000503	CcSEcCtD
Imatinib—Pruritus—Triamcinolone—ankylosing spondylitis	0.000152	0.000501	CcSEcCtD
Imatinib—Cough—Methotrexate—ankylosing spondylitis	0.000151	0.0005	CcSEcCtD
Imatinib—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000151	0.0005	CcSEcCtD
Imatinib—Convulsion—Methotrexate—ankylosing spondylitis	0.00015	0.000497	CcSEcCtD
Imatinib—Dyspepsia—Prednisone—ankylosing spondylitis	0.000149	0.000493	CcSEcCtD
Imatinib—Arthralgia—Methotrexate—ankylosing spondylitis	0.000148	0.000488	CcSEcCtD
Imatinib—Chest pain—Methotrexate—ankylosing spondylitis	0.000148	0.000488	CcSEcCtD
Imatinib—Myalgia—Methotrexate—ankylosing spondylitis	0.000148	0.000488	CcSEcCtD
Imatinib—Decreased appetite—Prednisone—ankylosing spondylitis	0.000147	0.000487	CcSEcCtD
Imatinib—Rash—Prednisolone—ankylosing spondylitis	0.000147	0.000486	CcSEcCtD
Imatinib—Dermatitis—Prednisolone—ankylosing spondylitis	0.000147	0.000485	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000147	0.000485	CcSEcCtD
Imatinib—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000146	0.000484	CcSEcCtD
Imatinib—Fatigue—Prednisone—ankylosing spondylitis	0.000146	0.000483	CcSEcCtD
Imatinib—Headache—Prednisolone—ankylosing spondylitis	0.000146	0.000483	CcSEcCtD
Imatinib—Discomfort—Methotrexate—ankylosing spondylitis	0.000146	0.000482	CcSEcCtD
Imatinib—Constipation—Prednisone—ankylosing spondylitis	0.000145	0.000479	CcSEcCtD
Imatinib—Confusional state—Methotrexate—ankylosing spondylitis	0.000143	0.000472	CcSEcCtD
Imatinib—Dizziness—Triamcinolone—ankylosing spondylitis	0.000142	0.000468	CcSEcCtD
Imatinib—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.000142	0.000468	CcSEcCtD
Imatinib—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000141	0.000467	CcSEcCtD
Imatinib—KIT—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000141	0.00768	CbGpPWpGaD
Imatinib—Infection—Methotrexate—ankylosing spondylitis	0.000141	0.000465	CcSEcCtD
Imatinib—PDGFRA—Allograft Rejection—IL1A—ankylosing spondylitis	0.00014	0.00767	CbGpPWpGaD
Imatinib—PDGFRA—Allograft Rejection—IL10—ankylosing spondylitis	0.00014	0.00762	CbGpPWpGaD
Imatinib—PDGFRA—Allograft Rejection—CD40LG—ankylosing spondylitis	0.00014	0.00762	CbGpPWpGaD
Imatinib—Feeling abnormal—Prednisone—ankylosing spondylitis	0.00014	0.000461	CcSEcCtD
Imatinib—Asthenia—Dexamethasone—ankylosing spondylitis	0.00014	0.000461	CcSEcCtD
Imatinib—Asthenia—Betamethasone—ankylosing spondylitis	0.00014	0.000461	CcSEcCtD
Imatinib—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000139	0.000459	CcSEcCtD
Imatinib—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.000139	0.000458	CcSEcCtD
Imatinib—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000139	0.000458	CcSEcCtD
Imatinib—Nausea—Prednisolone—ankylosing spondylitis	0.000138	0.000458	CcSEcCtD
Imatinib—Pruritus—Betamethasone—ankylosing spondylitis	0.000138	0.000455	CcSEcCtD
Imatinib—Pruritus—Dexamethasone—ankylosing spondylitis	0.000138	0.000455	CcSEcCtD
Imatinib—Skin disorder—Methotrexate—ankylosing spondylitis	0.000138	0.000454	CcSEcCtD
Imatinib—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.000137	0.000452	CcSEcCtD
Imatinib—Vomiting—Triamcinolone—ankylosing spondylitis	0.000136	0.00045	CcSEcCtD
Imatinib—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000136	0.000449	CcSEcCtD
Imatinib—Rash—Triamcinolone—ankylosing spondylitis	0.000135	0.000447	CcSEcCtD
Imatinib—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000135	0.000446	CcSEcCtD
Imatinib—Anorexia—Methotrexate—ankylosing spondylitis	0.000135	0.000446	CcSEcCtD
Imatinib—Rash—Methylprednisolone—ankylosing spondylitis	0.000135	0.000446	CcSEcCtD
Imatinib—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000135	0.000445	CcSEcCtD
Imatinib—Urticaria—Prednisone—ankylosing spondylitis	0.000135	0.000445	CcSEcCtD
Imatinib—Headache—Triamcinolone—ankylosing spondylitis	0.000134	0.000444	CcSEcCtD
Imatinib—Headache—Methylprednisolone—ankylosing spondylitis	0.000134	0.000443	CcSEcCtD
Imatinib—Body temperature increased—Prednisone—ankylosing spondylitis	0.000134	0.000443	CcSEcCtD
Imatinib—Abdominal pain—Prednisone—ankylosing spondylitis	0.000134	0.000443	CcSEcCtD
Imatinib—PDGFRA—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000133	0.00727	CbGpPWpGaD
Imatinib—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000133	0.00044	CcSEcCtD
Imatinib—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000133	0.00044	CcSEcCtD
Imatinib—PDGFRA—Allograft Rejection—HLA-B—ankylosing spondylitis	0.000133	0.00725	CbGpPWpGaD
Imatinib—Hypotension—Methotrexate—ankylosing spondylitis	0.000132	0.000437	CcSEcCtD
Imatinib—ABL1—Pathogenic Escherichia coli infection—TLR4—ankylosing spondylitis	0.000132	0.00721	CbGpPWpGaD
Imatinib—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.000129	0.000426	CcSEcCtD
Imatinib—Dizziness—Betamethasone—ankylosing spondylitis	0.000129	0.000425	CcSEcCtD
Imatinib—Dizziness—Dexamethasone—ankylosing spondylitis	0.000129	0.000425	CcSEcCtD
Imatinib—Insomnia—Methotrexate—ankylosing spondylitis	0.000128	0.000423	CcSEcCtD
Imatinib—Nausea—Triamcinolone—ankylosing spondylitis	0.000127	0.000421	CcSEcCtD
Imatinib—Paraesthesia—Methotrexate—ankylosing spondylitis	0.000127	0.00042	CcSEcCtD
Imatinib—Nausea—Methylprednisolone—ankylosing spondylitis	0.000127	0.00042	CcSEcCtD
Imatinib—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000126	0.000417	CcSEcCtD
Imatinib—Somnolence—Methotrexate—ankylosing spondylitis	0.000126	0.000416	CcSEcCtD
Imatinib—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000125	0.000412	CcSEcCtD
Imatinib—Dyspepsia—Methotrexate—ankylosing spondylitis	0.000125	0.000412	CcSEcCtD
Imatinib—KIT—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000124	0.00679	CbGpPWpGaD
Imatinib—Vomiting—Dexamethasone—ankylosing spondylitis	0.000124	0.000409	CcSEcCtD
Imatinib—Vomiting—Betamethasone—ankylosing spondylitis	0.000124	0.000409	CcSEcCtD
Imatinib—PDGFRA—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000123	0.00672	CbGpPWpGaD
Imatinib—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000123	0.000407	CcSEcCtD
Imatinib—Rash—Dexamethasone—ankylosing spondylitis	0.000123	0.000405	CcSEcCtD
Imatinib—Rash—Betamethasone—ankylosing spondylitis	0.000123	0.000405	CcSEcCtD
Imatinib—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000123	0.000405	CcSEcCtD
Imatinib—Dermatitis—Betamethasone—ankylosing spondylitis	0.000123	0.000405	CcSEcCtD
Imatinib—LCK—TCR signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000122	0.00668	CbGpPWpGaD
Imatinib—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000122	0.000404	CcSEcCtD
Imatinib—Fatigue—Methotrexate—ankylosing spondylitis	0.000122	0.000403	CcSEcCtD
Imatinib—Headache—Dexamethasone—ankylosing spondylitis	0.000122	0.000403	CcSEcCtD
Imatinib—Headache—Betamethasone—ankylosing spondylitis	0.000122	0.000403	CcSEcCtD
Imatinib—Asthenia—Prednisone—ankylosing spondylitis	0.000122	0.000402	CcSEcCtD
Imatinib—Pain—Methotrexate—ankylosing spondylitis	0.000121	0.0004	CcSEcCtD
Imatinib—PDGFRB—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.00012	0.00655	CbGpPWpGaD
Imatinib—Pruritus—Prednisone—ankylosing spondylitis	0.00012	0.000396	CcSEcCtD
Imatinib—PDGFRA—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000118	0.00643	CbGpPWpGaD
Imatinib—Feeling abnormal—Methotrexate—ankylosing spondylitis	0.000117	0.000386	CcSEcCtD
Imatinib—Diarrhoea—Prednisone—ankylosing spondylitis	0.000116	0.000383	CcSEcCtD
Imatinib—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000116	0.000383	CcSEcCtD
Imatinib—Nausea—Betamethasone—ankylosing spondylitis	0.000116	0.000382	CcSEcCtD
Imatinib—Nausea—Dexamethasone—ankylosing spondylitis	0.000116	0.000382	CcSEcCtD
Imatinib—Urticaria—Methotrexate—ankylosing spondylitis	0.000112	0.000372	CcSEcCtD
Imatinib—Dizziness—Prednisone—ankylosing spondylitis	0.000112	0.00037	CcSEcCtD
Imatinib—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000112	0.00037	CcSEcCtD
Imatinib—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000112	0.00037	CcSEcCtD
Imatinib—PTGS1—Overview of nanoparticle effects—TNF—ankylosing spondylitis	0.000112	0.0061	CbGpPWpGaD
Imatinib—LCK—IL12-mediated signaling events—HLA-A—ankylosing spondylitis	0.000111	0.00605	CbGpPWpGaD
Imatinib—NTRK1—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.000111	0.00604	CbGpPWpGaD
Imatinib—CA3—Metabolism—B3GNT2—ankylosing spondylitis	0.000111	0.00603	CbGpPWpGaD
Imatinib—LCK—Signaling by Interleukins—IL1RN—ankylosing spondylitis	0.00011	0.006	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—IL1R2—ankylosing spondylitis	0.000108	0.00592	CbGpPWpGaD
Imatinib—Vomiting—Prednisone—ankylosing spondylitis	0.000108	0.000356	CcSEcCtD
Imatinib—Rash—Prednisone—ankylosing spondylitis	0.000107	0.000353	CcSEcCtD
Imatinib—Dermatitis—Prednisone—ankylosing spondylitis	0.000107	0.000353	CcSEcCtD
Imatinib—PDGFRB—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000106	0.00579	CbGpPWpGaD
Imatinib—Headache—Prednisone—ankylosing spondylitis	0.000106	0.000351	CcSEcCtD
Imatinib—LCK—B Cell Receptor Signaling Pathway—CD79A—ankylosing spondylitis	0.000105	0.00574	CbGpPWpGaD
Imatinib—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000104	0.000345	CcSEcCtD
Imatinib—Asthenia—Methotrexate—ankylosing spondylitis	0.000102	0.000336	CcSEcCtD
Imatinib—Nausea—Prednisone—ankylosing spondylitis	0.000101	0.000332	CcSEcCtD
Imatinib—Pruritus—Methotrexate—ankylosing spondylitis	0.0001	0.000331	CcSEcCtD
Imatinib—Diarrhoea—Methotrexate—ankylosing spondylitis	9.69e-05	0.00032	CcSEcCtD
Imatinib—LCK—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	9.63e-05	0.00526	CbGpPWpGaD
Imatinib—Dizziness—Methotrexate—ankylosing spondylitis	9.36e-05	0.000309	CcSEcCtD
Imatinib—ABCG2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	9.35e-05	0.0051	CbGpPWpGaD
Imatinib—SLC22A2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	9.25e-05	0.00505	CbGpPWpGaD
Imatinib—Vomiting—Methotrexate—ankylosing spondylitis	9e-05	0.000297	CcSEcCtD
Imatinib—Rash—Methotrexate—ankylosing spondylitis	8.93e-05	0.000295	CcSEcCtD
Imatinib—Dermatitis—Methotrexate—ankylosing spondylitis	8.92e-05	0.000295	CcSEcCtD
Imatinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	8.9e-05	0.00486	CbGpPWpGaD
Imatinib—Headache—Methotrexate—ankylosing spondylitis	8.87e-05	0.000293	CcSEcCtD
Imatinib—KIT—B Cell Activation—CD79A—ankylosing spondylitis	8.78e-05	0.00479	CbGpPWpGaD
Imatinib—SLC22A1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	8.62e-05	0.00471	CbGpPWpGaD
Imatinib—KIT—Immune System—KIR3DL1—ankylosing spondylitis	8.54e-05	0.00466	CbGpPWpGaD
Imatinib—LCK—DAP12 interactions—HLA-C—ankylosing spondylitis	8.52e-05	0.00465	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—HLA-C—ankylosing spondylitis	8.51e-05	0.00464	CbGpPWpGaD
Imatinib—Nausea—Methotrexate—ankylosing spondylitis	8.41e-05	0.000278	CcSEcCtD
Imatinib—PDGFRA—B Cell Activation—CD79A—ankylosing spondylitis	8.32e-05	0.00454	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—ERAP1—ankylosing spondylitis	8.09e-05	0.00441	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—KIR3DL1—ankylosing spondylitis	8.08e-05	0.00441	CbGpPWpGaD
Imatinib—LCK—Signaling by Interleukins—IL1A—ankylosing spondylitis	7.91e-05	0.00432	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—IL17A—ankylosing spondylitis	7.78e-05	0.00425	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—CARD9—ankylosing spondylitis	7.7e-05	0.0042	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—ERAP1—ankylosing spondylitis	7.65e-05	0.00418	CbGpPWpGaD
Imatinib—PDGFRB—B Cell Activation—CD79A—ankylosing spondylitis	7.49e-05	0.00409	CbGpPWpGaD
Imatinib—CA9—Cellular responses to stress—IL1A—ankylosing spondylitis	7.41e-05	0.00405	CbGpPWpGaD
Imatinib—KIT—DAP12 interactions—HLA-B—ankylosing spondylitis	7.36e-05	0.00402	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—CARD9—ankylosing spondylitis	7.29e-05	0.00398	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—KIR3DL1—ankylosing spondylitis	7.28e-05	0.00397	CbGpPWpGaD
Imatinib—PTGS1—Selenium Micronutrient Network—CRP—ankylosing spondylitis	7.25e-05	0.00396	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—IL12B—ankylosing spondylitis	7.23e-05	0.00395	CbGpPWpGaD
Imatinib—ALB—Vitamin B12 Metabolism—CRP—ankylosing spondylitis	7.2e-05	0.00393	CbGpPWpGaD
Imatinib—CA14—Metabolism—B3GNT2—ankylosing spondylitis	7.12e-05	0.00389	CbGpPWpGaD
Imatinib—ABL1—Immune System—KIR3DL1—ankylosing spondylitis	7.1e-05	0.00387	CbGpPWpGaD
Imatinib—PDGFRA—DAP12 interactions—HLA-B—ankylosing spondylitis	6.97e-05	0.0038	CbGpPWpGaD
Imatinib—CA6—Metabolism—B3GNT2—ankylosing spondylitis	6.94e-05	0.00379	CbGpPWpGaD
Imatinib—PDGFRB—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	6.92e-05	0.00378	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—ERAP1—ankylosing spondylitis	6.9e-05	0.00376	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—CARD9—ankylosing spondylitis	6.57e-05	0.00358	CbGpPWpGaD
Imatinib—CA7—Metabolism—B3GNT2—ankylosing spondylitis	6.48e-05	0.00354	CbGpPWpGaD
Imatinib—ABL1—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—ankylosing spondylitis	6.42e-05	0.00351	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—CARD9—ankylosing spondylitis	6.4e-05	0.00349	CbGpPWpGaD
Imatinib—PDGFRB—DAP12 interactions—HLA-B—ankylosing spondylitis	6.28e-05	0.00343	CbGpPWpGaD
Imatinib—LCK—Host Interactions of HIV factors—HLA-A—ankylosing spondylitis	6.13e-05	0.00334	CbGpPWpGaD
Imatinib—LCK—B Cell Activation—CD79A—ankylosing spondylitis	6.01e-05	0.00328	CbGpPWpGaD
Imatinib—CA12—Metabolism—B3GNT2—ankylosing spondylitis	6e-05	0.00328	CbGpPWpGaD
Imatinib—KIT—Disease—ANTXR2—ankylosing spondylitis	5.97e-05	0.00326	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	5.9e-05	0.00322	CbGpPWpGaD
Imatinib—ALB—Folate Metabolism—CRP—ankylosing spondylitis	5.86e-05	0.0032	CbGpPWpGaD
Imatinib—LCK—Immune System—KIR3DL1—ankylosing spondylitis	5.84e-05	0.00319	CbGpPWpGaD
Imatinib—ALB—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	5.77e-05	0.00315	CbGpPWpGaD
Imatinib—PDGFRA—Disease—ANTXR2—ankylosing spondylitis	5.66e-05	0.00309	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—ERAP1—ankylosing spondylitis	5.53e-05	0.00302	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—IL1A—ankylosing spondylitis	5.32e-05	0.0029	CbGpPWpGaD
Imatinib—PDGFRA—Allograft Rejection—TNF—ankylosing spondylitis	5.32e-05	0.0029	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	5.29e-05	0.00289	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	5.29e-05	0.00289	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—CARD9—ankylosing spondylitis	5.27e-05	0.00288	CbGpPWpGaD
Imatinib—KIT—Immune System—IL1R2—ankylosing spondylitis	5.17e-05	0.00282	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	5.13e-05	0.0028	CbGpPWpGaD
Imatinib—PDGFRB—Disease—ANTXR2—ankylosing spondylitis	5.1e-05	0.00278	CbGpPWpGaD
Imatinib—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	5.05e-05	0.00276	CbGpPWpGaD
Imatinib—LCK—DAP12 interactions—HLA-B—ankylosing spondylitis	5.04e-05	0.00275	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	5.03e-05	0.00275	CbGpPWpGaD
Imatinib—KIT—Immune System—ERAP1—ankylosing spondylitis	4.9e-05	0.00268	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL1R2—ankylosing spondylitis	4.9e-05	0.00267	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—HLA-C—ankylosing spondylitis	4.84e-05	0.00264	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	4.66e-05	0.00254	CbGpPWpGaD
Imatinib—ALB—Selenium Micronutrient Network—CRP—ankylosing spondylitis	4.65e-05	0.00254	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—HLA-C—ankylosing spondylitis	4.64e-05	0.00253	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—ERAP1—ankylosing spondylitis	4.64e-05	0.00253	CbGpPWpGaD
Imatinib—CA2—Metabolism—B3GNT2—ankylosing spondylitis	4.59e-05	0.00251	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—HLA-C—ankylosing spondylitis	4.58e-05	0.0025	CbGpPWpGaD
Imatinib—KIT—Immune System—CARD9—ankylosing spondylitis	4.49e-05	0.00245	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL1R2—ankylosing spondylitis	4.41e-05	0.00241	CbGpPWpGaD
Imatinib—CA1—Metabolism—B3GNT2—ankylosing spondylitis	4.4e-05	0.0024	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—HLA-C—ankylosing spondylitis	4.4e-05	0.0024	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL1R2—ankylosing spondylitis	4.3e-05	0.00235	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CARD9—ankylosing spondylitis	4.25e-05	0.00232	CbGpPWpGaD
Imatinib—NTRK1—MAPK Signaling Pathway—TNF—ankylosing spondylitis	4.19e-05	0.00229	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—ERAP1—ankylosing spondylitis	4.18e-05	0.00228	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—HLA-C—ankylosing spondylitis	4.12e-05	0.00225	CbGpPWpGaD
Imatinib—LCK—Disease—ANTXR2—ankylosing spondylitis	4.09e-05	0.00223	CbGpPWpGaD
Imatinib—ABL1—Immune System—ERAP1—ankylosing spondylitis	4.08e-05	0.00222	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—HLA-C—ankylosing spondylitis	4.02e-05	0.00219	CbGpPWpGaD
Imatinib—LCK—HIV Infection—HLA-A—ankylosing spondylitis	3.98e-05	0.00217	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—HLA-C—ankylosing spondylitis	3.96e-05	0.00216	CbGpPWpGaD
Imatinib—CA9—Metabolism—B3GNT2—ankylosing spondylitis	3.87e-05	0.00211	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CARD9—ankylosing spondylitis	3.83e-05	0.00209	CbGpPWpGaD
Imatinib—NTRK1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	3.78e-05	0.00206	CbGpPWpGaD
Imatinib—ABL1—Immune System—CARD9—ankylosing spondylitis	3.73e-05	0.00203	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	3.69e-05	0.00201	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—CD79A—ankylosing spondylitis	3.54e-05	0.00193	CbGpPWpGaD
Imatinib—LCK—Immune System—IL1R2—ankylosing spondylitis	3.54e-05	0.00193	CbGpPWpGaD
Imatinib—KIT—Disease—B3GNT2—ankylosing spondylitis	3.52e-05	0.00192	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	3.49e-05	0.0019	CbGpPWpGaD
Imatinib—LCK—Immune System—ERAP1—ankylosing spondylitis	3.36e-05	0.00183	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—CD79A—ankylosing spondylitis	3.35e-05	0.00183	CbGpPWpGaD
Imatinib—PDGFRA—Disease—B3GNT2—ankylosing spondylitis	3.33e-05	0.00182	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—HLA-C—ankylosing spondylitis	3.31e-05	0.00181	CbGpPWpGaD
Imatinib—PTGS1—Selenium Micronutrient Network—TNF—ankylosing spondylitis	3.28e-05	0.00179	CbGpPWpGaD
Imatinib—ALB—Vitamin B12 Metabolism—TNF—ankylosing spondylitis	3.26e-05	0.00178	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	3.23e-05	0.00177	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—HLA-C—ankylosing spondylitis	3.18e-05	0.00173	CbGpPWpGaD
Imatinib—LCK—Immune System—CARD9—ankylosing spondylitis	3.07e-05	0.00168	CbGpPWpGaD
Imatinib—ABL2—Developmental Biology—TNF—ankylosing spondylitis	3.05e-05	0.00166	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—CD79A—ankylosing spondylitis	3.02e-05	0.00165	CbGpPWpGaD
Imatinib—PDGFRB—Disease—B3GNT2—ankylosing spondylitis	3e-05	0.00164	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—CD40LG—ankylosing spondylitis	2.89e-05	0.00158	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—HLA-B—ankylosing spondylitis	2.86e-05	0.00156	CbGpPWpGaD
Imatinib—KIT—Immune System—HLA-C—ankylosing spondylitis	2.82e-05	0.00154	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—HLA-B—ankylosing spondylitis	2.75e-05	0.0015	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—CD40LG—ankylosing spondylitis	2.73e-05	0.00149	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—HLA-B—ankylosing spondylitis	2.71e-05	0.00148	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HLA-C—ankylosing spondylitis	2.67e-05	0.00146	CbGpPWpGaD
Imatinib—ALB—Folate Metabolism—TNF—ankylosing spondylitis	2.65e-05	0.00145	CbGpPWpGaD
Imatinib—PDGFRA—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	2.62e-05	0.00143	CbGpPWpGaD
Imatinib—PDGFRB—MAPK Signaling Pathway—TNF—ankylosing spondylitis	2.62e-05	0.00143	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—HLA-B—ankylosing spondylitis	2.6e-05	0.00142	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—HLA-A—ankylosing spondylitis	2.54e-05	0.00139	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—CRP—ankylosing spondylitis	2.53e-05	0.00138	CbGpPWpGaD
Imatinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	2.48e-05	0.00135	CbGpPWpGaD
Imatinib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	2.48e-05	0.00135	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—CD40LG—ankylosing spondylitis	2.46e-05	0.00134	CbGpPWpGaD
Imatinib—KIT—Immune System—IL1RN—ankylosing spondylitis	2.45e-05	0.00134	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—HLA-B—ankylosing spondylitis	2.44e-05	0.00133	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD79A—ankylosing spondylitis	2.42e-05	0.00132	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—TLR4—ankylosing spondylitis	2.42e-05	0.00132	CbGpPWpGaD
Imatinib—LCK—Disease—B3GNT2—ankylosing spondylitis	2.41e-05	0.00132	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—HLA-A—ankylosing spondylitis	2.41e-05	0.00131	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HLA-C—ankylosing spondylitis	2.4e-05	0.00131	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—CRP—ankylosing spondylitis	2.39e-05	0.00131	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—HLA-B—ankylosing spondylitis	2.38e-05	0.0013	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—HLA-B—ankylosing spondylitis	2.34e-05	0.00128	CbGpPWpGaD
Imatinib—ABL1—Immune System—HLA-C—ankylosing spondylitis	2.34e-05	0.00128	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL1RN—ankylosing spondylitis	2.32e-05	0.00126	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—PTGER4—ankylosing spondylitis	2.31e-05	0.00126	CbGpPWpGaD
Imatinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	2.3e-05	0.00126	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—TLR4—ankylosing spondylitis	2.29e-05	0.00125	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—HLA-A—ankylosing spondylitis	2.17e-05	0.00118	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—CRP—ankylosing spondylitis	2.16e-05	0.00118	CbGpPWpGaD
Imatinib—KIT—Immune System—CD79A—ankylosing spondylitis	2.15e-05	0.00117	CbGpPWpGaD
Imatinib—ALB—Selenium Micronutrient Network—TNF—ankylosing spondylitis	2.11e-05	0.00115	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—CRP—ankylosing spondylitis	2.1e-05	0.00115	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL1RN—ankylosing spondylitis	2.09e-05	0.00114	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—TLR4—ankylosing spondylitis	2.07e-05	0.00113	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD79A—ankylosing spondylitis	2.03e-05	0.00111	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL1RN—ankylosing spondylitis	2.03e-05	0.00111	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—TLR4—ankylosing spondylitis	2.01e-05	0.0011	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	2.01e-05	0.0011	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD40LG—ankylosing spondylitis	1.98e-05	0.00108	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—HLA-B—ankylosing spondylitis	1.96e-05	0.00107	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—B3GNT2—ankylosing spondylitis	1.96e-05	0.00107	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—B3GNT2—ankylosing spondylitis	1.94e-05	0.00106	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—B3GNT2—ankylosing spondylitis	1.93e-05	0.00106	CbGpPWpGaD
Imatinib—LCK—Immune System—HLA-C—ankylosing spondylitis	1.93e-05	0.00105	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—HLA-B—ankylosing spondylitis	1.88e-05	0.00103	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—B3GNT2—ankylosing spondylitis	1.88e-05	0.00103	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD79A—ankylosing spondylitis	1.83e-05	0.001	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—B3GNT2—ankylosing spondylitis	1.8e-05	0.000984	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD79A—ankylosing spondylitis	1.79e-05	0.000974	CbGpPWpGaD
Imatinib—KIT—Immune System—IL1A—ankylosing spondylitis	1.76e-05	0.000961	CbGpPWpGaD
Imatinib—KIT—Immune System—CD40LG—ankylosing spondylitis	1.75e-05	0.000956	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—HLA-A—ankylosing spondylitis	1.74e-05	0.00095	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—CRP—ankylosing spondylitis	1.73e-05	0.000944	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PTGER4—ankylosing spondylitis	1.69e-05	0.000923	CbGpPWpGaD
Imatinib—LCK—Immune System—IL1RN—ankylosing spondylitis	1.67e-05	0.000914	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL1A—ankylosing spondylitis	1.67e-05	0.00091	CbGpPWpGaD
Imatinib—KIT—Immune System—HLA-B—ankylosing spondylitis	1.67e-05	0.000909	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—TLR4—ankylosing spondylitis	1.66e-05	0.000905	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD40LG—ankylosing spondylitis	1.66e-05	0.000905	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MMP3—ankylosing spondylitis	1.64e-05	0.000897	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PTGER4—ankylosing spondylitis	1.6e-05	0.000874	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HLA-B—ankylosing spondylitis	1.58e-05	0.000861	CbGpPWpGaD
Imatinib—KIT—Immune System—HLA-A—ankylosing spondylitis	1.54e-05	0.000842	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL1A—ankylosing spondylitis	1.5e-05	0.00082	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD40LG—ankylosing spondylitis	1.49e-05	0.000815	CbGpPWpGaD
Imatinib—KIT—Immune System—CRP—ankylosing spondylitis	1.47e-05	0.000804	CbGpPWpGaD
Imatinib—LCK—Immune System—CD79A—ankylosing spondylitis	1.47e-05	0.000802	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL1A—ankylosing spondylitis	1.46e-05	0.000799	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HLA-A—ankylosing spondylitis	1.46e-05	0.000797	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD40LG—ankylosing spondylitis	1.46e-05	0.000794	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PTGER4—ankylosing spondylitis	1.44e-05	0.000787	CbGpPWpGaD
Imatinib—KIT—Disease—HLA-A—ankylosing spondylitis	1.42e-05	0.000778	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HLA-B—ankylosing spondylitis	1.42e-05	0.000775	CbGpPWpGaD
Imatinib—KIT—Immune System—TLR4—ankylosing spondylitis	1.41e-05	0.00077	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—B3GNT2—ankylosing spondylitis	1.4e-05	0.000765	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CRP—ankylosing spondylitis	1.39e-05	0.000761	CbGpPWpGaD
Imatinib—ABL1—Immune System—HLA-B—ankylosing spondylitis	1.38e-05	0.000756	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HLA-A—ankylosing spondylitis	1.35e-05	0.000736	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—TLR4—ankylosing spondylitis	1.34e-05	0.000729	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HLA-A—ankylosing spondylitis	1.32e-05	0.000718	CbGpPWpGaD
Imatinib—ABL1—Immune System—HLA-A—ankylosing spondylitis	1.28e-05	0.0007	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CRP—ankylosing spondylitis	1.26e-05	0.000685	CbGpPWpGaD
Imatinib—ABL1—Immune System—CRP—ankylosing spondylitis	1.22e-05	0.000668	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HLA-A—ankylosing spondylitis	1.22e-05	0.000663	CbGpPWpGaD
Imatinib—ALB—Metabolism—B3GNT2—ankylosing spondylitis	1.21e-05	0.000658	CbGpPWpGaD
Imatinib—LCK—Immune System—IL1A—ankylosing spondylitis	1.21e-05	0.000658	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MMP3—ankylosing spondylitis	1.2e-05	0.000657	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—TLR4—ankylosing spondylitis	1.2e-05	0.000657	CbGpPWpGaD
Imatinib—LCK—Immune System—CD40LG—ankylosing spondylitis	1.2e-05	0.000654	CbGpPWpGaD
Imatinib—ABL1—Immune System—TLR4—ankylosing spondylitis	1.17e-05	0.00064	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PTGER4—ankylosing spondylitis	1.16e-05	0.000632	CbGpPWpGaD
Imatinib—LCK—Immune System—HLA-B—ankylosing spondylitis	1.14e-05	0.000622	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MMP3—ankylosing spondylitis	1.14e-05	0.000622	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—B3GNT2—ankylosing spondylitis	1.08e-05	0.000591	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—TNF—ankylosing spondylitis	1.08e-05	0.000588	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	1.06e-05	0.000577	CbGpPWpGaD
Imatinib—LCK—Immune System—HLA-A—ankylosing spondylitis	1.06e-05	0.000576	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MMP3—ankylosing spondylitis	1.03e-05	0.000561	CbGpPWpGaD
Imatinib—LCK—Immune System—CRP—ankylosing spondylitis	1.01e-05	0.00055	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—B3GNT2—ankylosing spondylitis	9.96e-06	0.000544	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	9.93e-06	0.000542	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—B3GNT2—ankylosing spondylitis	9.87e-06	0.000539	CbGpPWpGaD
Imatinib—LCK—Disease—HLA-A—ankylosing spondylitis	9.75e-06	0.000532	CbGpPWpGaD
Imatinib—LCK—Immune System—TLR4—ankylosing spondylitis	9.66e-06	0.000527	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—B3GNT2—ankylosing spondylitis	8.44e-06	0.000461	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MMP3—ankylosing spondylitis	8.24e-06	0.00045	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	6.51e-06	0.000355	CbGpPWpGaD
